EULAR Express . . . Data on the efficacy and safety of Bellitum was confirmed in the population with active lupus nephritis.

From June 3 to June 6, 2020, the European rheumatic Association (EULAR) held the European annual meeting on rheumatism online.in this annual meeting, the largest bliss-ln study of lupus nephritis was first presented in today's theme report, and became one of the most remarkable academic focuses, and the research results are encouraging.following the remarkable achievements of three global multicenter phase III clinical trials bliss-52, bliss-76 and Northeast Asia studies, baileyumab has conquered the dangerous peak of lupus nephritis again: up to now, the world's largest active lupus nephritis randomized, controlled, 104 week phase III clinical trial (bliss-ln) has reached the primary endpoint and all secondary endpoints.bliss-ln: a randomized, double-blind, global, phase III study to evaluate the efficacy and safety of baileyumab for injection in patients with active lupus erythematosus. Background: kidney is the most frequently involved organ in systemic lupus erythematosus (SLE). Lupus nephritis (LN) is also one of the serious complications of SLE. 70% of SLE patients will be accompanied by lupus nephritis.to control renal injury as soon as possible, protect renal function and improve long-term survival rate of human and kidney are the treatment objectives of LN.despite the progress of medicine, the proportion of patients with lupus nephritis progressing to end-stage renal disease (ESRD) in 15 years is still more than 40%.in a post-mortem analysis of a global multicenter phase III bliss-52 / 76 study, it was found that belizumab can improve renal parameters in lupus patients with baseline renal involvement.Objective: To evaluate the efficacy and safety of baileyumab for injection combined with standard therapy in patients with active lupus nephritis.methods: bliss-ln (GSK study bel14054, nct01639339) was a randomized, double-blind, controlled, 104 week global multicenter phase III clinical study.patients with LN (III, IV, V or III + V or IV + V) confirmed by recent renal biopsy and requiring induction therapy were included in the study.448 patients with LN were randomly divided into "baileyumab 10mg / kg + standard treatment group" or "placebo + standard treatment group" at 1:1.primary end point: perR at 104 weeks (defined as urinary protein creatinine ratio upcr ≤ 0.7; and EGFR reduction ≤ 20% before recurrence or ≥ 60 ml / min / 1.73m2; and no rescue treatment).key secondary endpoint: complete remission rate (CRR) at 104 weeks (defined as upcr & lt; 0.5; And EGFR reduction ≤ 10% before recurrence or ≥ 90 mL / min / 1.73m2; and no rescue treatment); 52 weeks perR; lead to death or to the time of kidney related events (ESRD / double increase of serum creatinine / renal deterioration / failure of renal related treatment); overall renal remission (ORR) after two years.results: at 104 weeks, more patients in the "baileyumab + standard treatment group" achieved the primary end point perR (43.0% vs. 32.3%, or 1.55, 95% CI (1.04, 2.32), P = 0.0311).more patients in the baileyumab group reached the key secondary endpoint, and the differences were statistically significant.compared with the placebo + standard treatment group, patients treated with baileyumab had a higher proportion of achieving and maintaining perR and CRR, and the baileyumab treatment group significantly reduced the risk of kidney related events within 104 weeks.at the end point of safety, baileyumab was comparable to placebo group.Table 1: primary end points and key secondary efficacy endpoints. Results: bliss-ln study is the largest clinical study of lupus nephritis so far, The efficacy and safety data of baileyumab have been confirmed in active lupus nephritis population. Compared with the traditional treatment, baileyumab combined with standard treatment can significantly improve the renal response of patients with lupus nephritis, with good safety.edited by: Zhang Yuhui reviewed by: Xinya medical journal Public email: yishibao2017@163.com [note] some of the pictures are from the network and wechat circle of friends. Dear Author, the doctor's Daily has prepared the contribution fee for you. Please contact the editor on duty at 58302828-6808 for past review A kind of What is the child thinking when you smoke? This eight minute video tells you A kind of Hospital headlines | women love to eat barbecue "five cooked" and suffer from rare hepatic echinococcosis A kind of Zhao Jiajun, President of Shandong Provincial Hospital A kind of The live broadcasting room of "doctor's Daily" is heavily attacked, with 60 live broadcasts and more than 8 million people participating. There is no distance between the authority and you! A kind of Share your 15 years of medical experience A kind of Reading is a kind of power when the latest 645 issue of "doctor's Daily" is released A kind of Self directed and self performed micro film by doctor newspaper! A kind of [Video] 2019 doctor's Daily: pay homage to life and doctors A kind of [Video] 2018 doctor's Daily: creating a butterfly for your dream! Look for someone else! Looking for professional and dedicated person! Look for diligent and responsible people! West 2nd Ring Road, Beijing New Shijing office, waiting for you! New media operation director 1 senior medical editor 5 fusion media reporters resume please send to: yishibao2017@163.com At present, 1130000 + doctors have paid attention to join us